ON-DEMAND WEBINARS

Led by Dr. Richard Johnson, Chief Scientific Officer, this 40-minute session covers the five key stages of the UpperNose development platform, highlighting the significance of target product selection and its influence on formulation and clinical outcomes.

Delve into the intricacies of combination products and the regulatory expectations, including risk-based determination, evaluation, and documentation approaches for performance requirements.

Gain valuable insights into the jet milling process and Quality by Design approach for inhalation drug delivery and their potential applications in drug development.

Discover how pharma companies can select tailored pre-filled syringes for biologics and biosimilars by aligning drug delivery needs with specialized containers and analytical services.

ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS

TVG-New

Fran DeGrazio, Executive Editor - Drug Delivery Leader & Frankly Fran

Fran offers keen industry and technical insights exclusively on Drug Delivery Leader.

DELIVERED BY DEGRAZIO

  • Unpacking The FDA Draft Guidance On Container Closure Systems

    In this article, Fran DeGrazio reflects on the significance of the FDA Draft Guidance on Container Closure Systems, the first update since 1999. DeGrazio places the CCS draft guidance in the current context of science-based and risk-based product development for combination products and other injectable drug product delivery systems. She also addresses the integration of CCS guidance into the development organization’s QMS (Quality Management System).

FREE EBOOK

DRUG DISCOVERY CONTENT COLLECTIONS

Why Human Factors Are Critical To Drug Delivery Device Success

In today’s highly competitive biopharma market, successful therapies prioritize the patient experience. Increasingly, patients expect to receive advanced therapies at home or in decentralized care settings, which require delivery methods that are easy to use and comfortable.

This collection explores how drug delivery teams can incorporate patient-centricity across development, from early human factors strategies to modality selection, ensuring safe, effective therapies that translate to real-world care.

Download The eBook Now

More Content Collections